Go Pro

Travere Therapeutics (TVTX) 10K Form and Latest SEC Filings 2026

Travere Therapeutics logo
$56.90 -0.02 (-0.04%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$58.78 +1.88 (+3.30%)
As of 07/2/2026 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Travere Therapeutics SEC Filings & Recent Activity

Travere Therapeutics (NASDAQ:TVTX) has submitted 575+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Travere Therapeutics's financial statements. The most recent filing was a Form 4 submitted on June 22, 2026.

Form 4
Travere Therapeutics, Inc. Reports Ownership Change on Jun. 22, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Travere Therapeutics Files Current Report on Jun. 16, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Travere Therapeutics Files Quarterly Report on May. 4, 2026

The 10-Q contains Travere Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Travere Therapeutics SEC Filing History

Browse Travere Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
06/22/2026 3:37 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2026 3:32 PM
Travere Therapeutics (1438533) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
06/16/2026 3:42 PM
Baynes Roy D. (1680739) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 3:46 PM
Coughlin Timothy (1376043) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 3:34 PM
Travere Therapeutics (1438533) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/12/2026 3:05 PM
Baynes Roy D. (1680739) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/12/2026 11:20 AM
Coughlin Timothy (1376043) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/02/2026 6:05 AM
Travere Therapeutics (1438533) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/19/2026 3:05 PM
Coughlin Timothy (1376043) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2026 11:51 AM
Coughlin Timothy (1376043) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/15/2026 10:17 AM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Travere Therapeutics (1438533) Subject
Form SCHEDULE 13G
05/11/2026 4:10 PM
Travere Therapeutics (1438533) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2026 5:01 AM
Travere Therapeutics (1438533) Subject
Form FWP
05/06/2026 7:00 PM
Cline Christopher R. (1943192) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2026 7:00 PM
Dube Eric M (1763494) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2026 7:00 PM
Heerma Peter (1789617) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2026 7:00 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2026 7:00 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2026 7:00 PM
ROTE WILLIAM E. (1698262) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2026 7:00 PM
Meckler Jeffrey A (1506916) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2026 7:00 PM
Baynes Roy D. (1680739) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2026 3:02 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/06/2026 3:03 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/06/2026 3:03 PM
Cline Christopher R. (1943192) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/06/2026 8:55 AM
Dube Eric M (1763494) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/06/2026 8:37 AM
ROTE WILLIAM E. (1698262) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/05/2026 6:48 PM
Cline Christopher R. (1943192) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/05/2026 6:31 PM
Heerma Peter (1789617) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/05/2026 6:31 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/05/2026 6:32 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/05/2026 3:04 PM
Travere Therapeutics (1438533) Filer
Form 424B5
05/04/2026 3:45 PM
Travere Therapeutics (1438533) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/04/2026 3:03 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/04/2026 3:04 PM
Meckler Jeffrey A (1506916) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/04/2026 3:04 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/04/2026 3:05 PM
Travere Therapeutics (1438533) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2026 3:15 PM
Baynes Roy D. (1680739) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/23/2026 3:05 PM
ROTE WILLIAM E. (1698262) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 9:36 AM
ROTE WILLIAM E. (1698262) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/16/2026 3:05 PM
LYONS GARY A (1123343) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 8:46 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad)

Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel

See which companies control the supply chain behind this emerging tech
04/15/2026 8:46 PM
Cline Christopher R. (1943192) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 8:47 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 8:48 PM
Dube Eric M (1763494) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 8:48 PM
ROTE WILLIAM E. (1698262) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 8:49 PM
Heerma Peter (1789617) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:13 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/15/2026 3:14 PM
Cline Christopher R. (1943192) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/15/2026 3:15 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/15/2026 3:16 PM
Dube Eric M (1763494) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/14/2026 8:17 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/14/2026 7:47 PM
Heerma Peter (1789617) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/14/2026 7:53 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/14/2026 7:40 PM
Cline Christopher R. (1943192) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/14/2026 3:27 PM
LYONS GARY A (1123343) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/14/2026 3:19 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/14/2026 3:20 PM
Cline Christopher R. (1943192) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/14/2026 3:02 PM
Calvin Sandra (1882909) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/14/2026 3:09 PM
Baynes Roy D. (1680739) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/13/2026 7:44 PM
Travere Therapeutics (1438533) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/13/2026 7:11 PM
Cline Christopher R. (1943192) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/07/2026 5:17 PM
Baynes Roy D. (1680739) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/06/2026 3:07 PM
Travere Therapeutics (1438533) Filer
Form DEF 14A
04/06/2026 3:09 PM
Travere Therapeutics (1438533) Filer
Form DEFA14A
04/06/2026 3:10 PM
Travere Therapeutics (1438533) Filer
Form ARS
04/02/2026 4:55 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 4:55 PM
Dube Eric M (1763494) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 3:06 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/27/2026 12:33 PM
Travere Therapeutics (1438533) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/16/2026 3:20 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/20/2026 3:49 PM
Dube Eric M (1763494) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/19/2026 3:47 PM
Travere Therapeutics (1438533) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/19/2026 3:10 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 8:38 PM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Travere Therapeutics (1438533) Subject
Form SCHEDULE 13G/A
02/17/2026 3:30 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/13/2026 5:13 AM
MACQUARIE GROUP LTD (1418333) Filed by
Travere Therapeutics (1438533) Subject
Form SCHEDULE 13G/A
02/09/2026 7:10 AM
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Travere Therapeutics (1438533) Subject
Form SCHEDULE 13G
02/04/2026 3:06 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2026 3:07 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2026 5:00 AM
Heerma Peter (1789617) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/03/2026 8:59 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/03/2026 8:45 PM
Cline Christopher R. (1943192) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/03/2026 8:58 PM
Calvin Sandra (1882909) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/03/2026 8:30 PM
REED ELIZABETH E (1283303) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 8:30 PM
Calvin Sandra (1882909) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 8:30 PM
ROTE WILLIAM E. (1698262) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 8:30 PM
Heerma Peter (1789617) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 8:30 PM
Cline Christopher R. (1943192) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 8:30 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 8:30 PM
Dube Eric M (1763494) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 8:37 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Your book attached (Ad)

Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel

Download the Safe Trade Options Formula book for free before access closes
02/03/2026 10:38 AM
Dube Eric M (1763494) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/03/2026 9:05 AM
ROTE WILLIAM E. (1698262) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/27/2026 7:25 PM
Dube Eric M (1763494) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2026 3:14 PM
Dube Eric M (1763494) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/13/2026 3:32 PM
Travere Therapeutics (1438533) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/12/2026 4:04 PM
Travere Therapeutics (1438533) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2026 8:09 AM
FMR LLC (315066) Filed by
Travere Therapeutics (1438533) Subject
Form SCHEDULE 13G
01/07/2026 3:05 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:07 PM
Inrig Jula (1902368) Reporting
Travere Therapeutics (1438533) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Travere Therapeutics SEC Filings - Frequently Asked Questions

Travere Therapeutics (TVTX) has submitted 575+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Travere Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Travere Therapeutics's financial statements page.

The most recent filing was a Form 4 submitted on June 22, 2026. This was an insider ownership change filed by 4 - Travere Therapeutics, Inc. (0001438533) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:TVTX) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners